J.Jpn. Surg. Soc.. 90(7): 980-987, 1989

---

Original article

AN EXPERIMENTAL STUDY ON ANTITUMOR EFFECT OF PROSTAGLANDIN D₂

The cell growth inhibitory effects of prostaglandin D₂ (PGD₂) were examined on cultured and implanted malignant tumor cell lines. The results were as follows.
1) PGD₂ showed the significant cytotoxicity against Sarcoma-180, Ehrlich cancer, Yoshida sarcoma and KATO-III in culture. The cytotoxicity of PGD₂ against KATO-III was the lowest.
2) PGD₂ at a dose of 40μg/mouse/day was intraperitoneally injected into ddY mice for 10 days starting on the first day after an intraperitoneal implant of 2×10⁵ Sarcoma-180 cells. As a result, the duration of survival was significantly prolonged. However, intravenous injection was less effective than intraperitoneal injection.
3) Addition of Forskolin to the cultured KATO-III cells with PGD₂ resulted in a significant increase of cyclic AMP (cAMP) levels. However, the growth inhibition of PGD₂ was independent of elevated levels of cAMP.
4) DNA histograms using flow cytometry showed PGD₂ blocked significantly G₂+M phases DNA synthesis in the cultured Sarcoma-180 cells, and S phase DNA synthesis in KATO-III cells was significantly blocked with PGD₂ at a concentration of 100μg/ml.
The results indicate that PGD₂ possesses an antitumor effect on 4 malignant tumor cell lines. Furthermore, it seems that the antitumor mechanism of PGD₂ is due to the inhibition of DNA synthesis rather than the action through cAMP-receptor, and the blockade to cell cycle progression is dependent on kinds of tumor cell lines.

Go to Page Top

---

To read the PDF file you will need Adobe Reader installed on your computer.